VVEO3.SA CM Hospitalar SA
- Market cap
- BRL 212M
- P/E
- 3.7x
- P/B
- 0.11x
- ROE
- -10.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is VVEO3.SA undervalued?
Graham numberThe Graham number of CM Hospitalar SA cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CM Hospitalar SA fundamental analysis
No fundamental analysis for CM Hospitalar SA yet.
CM Hospitalar SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CM Hospitalar SA
CM Hospitalar S/A engages in the distribution of hospital materials, medicines, and nutrition products in Brazil. The company offers material products for cardiac, surgical, urinary, diagnosis, sterilization, wound management, hygiene and protection, infusion, clinical nutrition, orthopedic, and respiratory; and medications, such as painkillers, anesthetics, anti-allergy, antibiotics, antiemetics, antifungals, anti-inflammatory, special control, several, and oncology. It als…
Full company profileCM Hospitalar SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CM Hospitalar SA annual financial statements (BRL; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.70B | 2.64B | 3.00B | 4.41B | 6.22B | 8.75B | 11.1B | 11.6B | 11.6B | 11.5B |
| Gross Profit | 201M | 399M | 469M | 638M | 1.09B | 1.40B | 1.73B | 1.30B | 1.67B | 1.86B |
| Operating Income | 61.0M | 109M | 123M | 211M | 492M | 510M | 636M | -863M | 532M | 521M |
| EBITDA | 88.0M | 164M | 120M | 310M | 615M | 721M | 1.06B | -791M | 967M | 845M |
| Net Income | 58.8M | 34.1M | 35.7M | 122M | 395M | 260M | 360M | -1.42B | 18.2M | -183M |
| EPS | 0.21 | 0.12 | 0.12 | 0.43 | 1.57 | 0.92 | 1.12 | -4.48 | 0.06 | -0.58 |
| Balance Sheet | ||||||||||
| Total Assets | 1.41B | 2.15B | 2.09B | 4.60B | 6.90B | 9.56B | 10.2B | 9.54B | 8.98B | 8.76B |
| Total Liabilities | 1.06B | 1.80B | 1.71B | 3.39B | 4.75B | 7.28B | 6.90B | 7.62B | 7.05B | 6.94B |
| Shareholders' Equity | 350M | 355M | 382M | 1.20B | 2.15B | 2.28B | 3.29B | 1.93B | 1.94B | 1.82B |
| Cash & Short-term Investments | 62.3M | 302M | 279M | 1.03B | 2.20B | 2.02B | 1.00B | 1.13B | 659M | 387M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 54.2M | 85.8M | 163M | 186M | 320M | 533M | -896M | 34.2M | 277M | 33.3M |
| Capital Expenditure | 3.28M | 27.8M | 20.5M | 49.4M | 78.0M | 152M | 376M | 185M | 166M | 120M |
| Free Cash Flow | 41.2M | 57.9M | 137M | 132M | 88.3M | 273M | -1.20B | -151M | 125M | -87.0M |
| Ratios | ||||||||||
| ROE | 16.8% | 9.6% | 9.4% | 10.1% | 18.4% | 11.4% | 10.9% | -73.5% | 0.9% | -10.1% |
| ROA | 4.2% | 1.6% | 1.7% | 2.6% | 5.7% | 2.7% | 3.5% | -14.8% | 0.2% | -2.1% |
| Net Profit Margin | 3.5% | 1.3% | 1.2% | 2.8% | 6.4% | 3.0% | 3.2% | -12.2% | 0.2% | -1.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CM Hospitalar SA dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 2, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | BRL 43.5M | 0.14 | - |
| 2023 | BRL 74.7M | 0.23 | 20.8% |
| 2022 | BRL 45.0M | 0.16 | 17.3% |
| 2021 | BRL 45.0M | 0.18 | 11.4% |
| 2020 | BRL 45.0M | 0.16 | 37.0% |
| 2019 | BRL 45.0M | 0.16 | 125.9% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns CM Hospitalar SA
- Insiders 3.94%
- Institutions 12.37%
- Public & others 83.69%
- Shares outstanding 316M
- Free float 192M
CM Hospitalar SA company profile
- Company name
- CM Hospitalar SA
- Ticker
- VVEO3.SA
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 6,000
- Fiscal year end
- December
- Address
- Av. Alfredo Egídio de Souza Aranha, São Paulo, SP, Brazil, 04726-170
- Phone
- 55 11 99379 6999
- Website
- ri.viveo.com.br
About CM Hospitalar SA
CM Hospitalar S/A engages in the distribution of hospital materials, medicines, and nutrition products in Brazil. The company offers material products for cardiac, surgical, urinary, diagnosis, sterilization, wound management, hygiene and protection, infusion, clinical nutrition, orthopedic, and respiratory; and medications, such as painkillers, anesthetics, anti-allergy, antibiotics, antiemetics, antifungals, anti-inflammatory, special control, several, and oncology. It also provides materials for respiratory assistance, therapy, anti-inflammatories, anti-tnf, antacid, antiandrogens, antianemics, anti-asthmatics, antibiotics, anticoagulant, anticonvulsant, monoclonal antibody, anti-growth, antidepressants, antidiabetic drug, antidiuretics, antidote, antiemetics and antinauseants, anti-migraine, antiepileptics, antiestrogens, antifibrinolytics, antiflatulents, antifungals, antihemorrhagic drug, antimicrobial, antineoplastics, antiparathyroid, antiparkinsonian, antipsychotics, systemic antipsoriasis, antirheumatic drugs, anti-varicose, antivirals, beta-blockers, carbohydrate, cycloplegic, contraceptives, contrast, special control, corticosteroids, topical debriding agent, diuretics, several, electrolyte, pancreatic enzyme, erythropoietins, uterine stimulant, cardiac stimulators, growth factor, granulocyte colony stimulating factor, gastroprokinetics, systemic hemostatics, heparins, hepatoprotective and lipotropic agents, hormone, adenohypophyseal hormones, growth hormones, immunoglobulins, immunosuppressants, labor induction drugs, proton pump inhibitor, phosphodiesterase and bone resorption inhibitor, platelet aggregation inhibitors, adenosine diphosphate receptor antagonists, proton pump inhibitors, interleukin inhibitors, subtilisin/kexin type 9 proprotein convertase inhibitors, calcium reabsorption inhibitors, materials, medications, nutrition, therapy, orthopedic therapy. CM Hospitalar S/A was incorporated in 2010 and is headquartered in São Paulo, Brazil.
CM Hospitalar SA management
6- André Clark JulianoCEO & Member of Management Board
- Frederico de Aguiar OldaniMember of Management Board and VP of Administration & Finance
- Flavia de Lima CarvalhoMember of Management Board & Director of Investor Relations and M&A
- Renan de Almeida HervelhaCommercial Director & Member of Management Board
- Mr. Luiz Augusto de Lima e Silva FilhoMember of Management Board & VP of Operations
- Artur de Barros AvancineVice President of Capital Human & ESG and Member of Management Board